Arbutus Biopharma’s (ABUS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a report published on Thursday,Benzinga reports. They currently have a $5.00 price objective on the biopharmaceutical company’s stock.

Several other analysts also recently commented on ABUS. Chardan Capital raised their price objective on Arbutus Biopharma from $4.00 to $4.50 and gave the stock a “buy” rating in a research note on Wednesday. StockNews.com upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 10th. Jefferies Financial Group boosted their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Finally, JMP Securities raised their price target on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.38.

Arbutus Biopharma Stock Performance

ABUS traded up $0.03 during trading on Thursday, reaching $3.76. 585,065 shares of the company’s stock were exchanged, compared to its average volume of 1,111,542. The company’s fifty day moving average price is $4.04 and its 200-day moving average price is $3.58. The firm has a market capitalization of $709.81 million, a PE ratio of -8.77 and a beta of 1.92. Arbutus Biopharma has a fifty-two week low of $1.70 and a fifty-two week high of $4.72.

Institutional Investors Weigh In On Arbutus Biopharma

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its holdings in Arbutus Biopharma by 19.7% in the 1st quarter. BNP Paribas Financial Markets now owns 349,435 shares of the biopharmaceutical company’s stock valued at $902,000 after acquiring an additional 57,390 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Arbutus Biopharma during the first quarter worth about $266,000. Verus Capital Partners LLC increased its holdings in Arbutus Biopharma by 30.5% in the 1st quarter. Verus Capital Partners LLC now owns 41,935 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 9,800 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Arbutus Biopharma by 22.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 6,649 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its position in shares of Arbutus Biopharma by 12.7% in the 1st quarter. Kennedy Capital Management LLC now owns 436,506 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 49,265 shares in the last quarter. 43.79% of the stock is currently owned by institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.